Please type a plus sign (+) inside this box [+]

PTO/SB/8A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/032,281
Filing Date	December 21, 2001
First Named Inventor	WYRICK, JOHN
Group Art Unit	1637
Examiner Name	Fredman, Jeffrey Norman
Attorney Docket Number	10050560-1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (*if known*)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	6,982,145		Mercola et al.	01-03-2006	
	A2					
	A3					

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[2] (*if known*)	Country	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	B1	WO	02/14550		PCT	02-21-2002		
	B2	WO	04/053106		PCT	06-24-2004		
	B3	WO	04/087965		PCT	10-14-2004		
	B4	WO	04/097577		PCT	11-11-2004		
	B5	WO	05/054461		PCT	06-16-2005		
	B6							
	B7							

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	C1	BAR-JOSEPH et al., "Computational discovery of gene modules and regulatory networks," Nature Biotechnology, 21(11):1337-1342 (2003)
	C2	BIGLER et al., "Isolation of a Thyroid Hormone-Responsive Gene by Immunoprecipitatio of Thyroid Hormone Receptor-DNA Complexes", Molecular and Cellular Biology, 14:7621-7632 (1994)
	C3	BIGLER et al., Novel location and function of a thyroid hormone response element," The EMBO Journal, 14-5710-5723 (1995)
	C4	BOTQUIN et al., "New POU dimmer configuration mediates antagonistic control of an osteopontin preimplanatation enhancer by Oct-4 and Sox-2," Genes & Development, 12:2073-2090 (1998).
	C5	COHEN-KAMINSKY et al., "Chromatin immunoselection defines a TAL-1 target," The EMBO Journal, 17:5151-5160 (1998)
	C6	DEVEAUX et al., "p45 NF-E2 regulates expression of thromboxane synthase in megakaryocytes," The EMBO Journal, 18:5654-5661 (1997)
	C7	GOULD et al., "Targets of homeotic gene control in Drosophila," Nature 348:308-312 (1990)

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

1091347_1.DOC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Please type a plus sign (+) inside this box [+] PTO/SB/8B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	10/032,281
Filing Date	December 21, 2001
First Named Inventor	Wyrick, John
Group Art Unit	1637
Examiner Name	Fredman, Jeffrey Norman
Attorney Docket Number	10050560-1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	C8	GOULD et al., "Connectin, a target of homeotic gene control in Drosophila," Development 116:1163-1174 (1992)	
	C9	GRABA et al., "Homeotic control in Drosophilia; the scabrous gene is an *in vivo* target of Ultrabithorax proteins," The EMBO Journal 11:3375-3384 (1992)	
	C10	GRABA et al., "DWnt-4, a novel Drosophila Wnt gene acts downstream of homeotic complex genes in the visceral mesoderm," Development 121:209-218 (1990)	
	C11	GRABA et al., "Drosophila Hox complex downstream targets and the function of Homeotic genes," BioEssays 19(5):379-388 (1991)	
	C12	GRANDORI et al., "Myc-Max heterodimers activate a DEAD box gene and interact with multiple E box-related sites *in vivo*," The EMBO Journal 15:4344-4357 (1996)	
	C13	HALLAHAN et al., "c-jun and Egr-1 Participate in DNA Synthesis and Cell Survival in Response to Ionizing Radiation Exposure," J. Biol Chem. 270(51):30303-30309 (1994)	
	C14	HARTEMINK et al., "Combining location and expression data for principled discovery of genetic regulatory network models," Proceedings of the Pacific Symposium on Biocomputing, 437-449 (2002)	
	C15	KOHWI-SHIGEMATSU et al., "Identification of Base-Unpairing Region-Binding Proteins and Characterization of Their *in Vivo* Binding Sequences," Methods of Cell Biology 53:323-354 (1998)	
	C16	Lee et al., "Transcriptional Regulatory Networks in Saccharomyces cerevisiae," Science, 298:799-804 (2002)	
	C17	MUKHERJEE et al., "Rapid analysis of the DNA binding specificities of transcription factors with DNA microarrays," Nature Genetics, 36(12):1331-1339, (2004)	
	C18	NICKERSON et al., "The nuclear matrix revealed by eluting chromatin from a cross-lined nucleus," Proc. Natl. Acad. Sci. USA 94:4446-4450 (1997)	
	C19	ODOM et al., "Control of Pancreas and Liver Gene Expression by HNF Transcription Factors," Science, 303(5662):1378-1381 (2004)	
	C20	ORLANDO et al., Mapping Polycomb-Repressed Domains in the Bithroax Complex Using In Vivio Formaldehyde Cross-Linked Chromatin," Cell, 75:187-1198 (1993)	
	C21	ORLANDO et al., "Analysis of Chromatin Structure by in Vivo Cormaldehyde Cross-Linking," METHODS: a Companion to Methods in Enzymology, 11:205-214 (1997)	
	C22	PRADEL et al., "From selectors to realizators," Int. J. Dev. Biol. 42:417-421 (1992)	
	C23	SCHOUTEN, The Journal of Biol. Chem. 260:9929-9935 (1985)	
	C24	SOLOMON et al., "Formaldehyde-Mediated DNA-Protein Crosslinking: A Probe for In Vivo Chromatine Structures," Proc. Natl. Acad. Sci. USA 82:6470-6474 (October 1985)	
	C25	TOMOTSUNE, "A mouse homologue of the Drosophila tumour-suppressor gene 1(2)gl controlled by Hox-C8 In vivo," Nature 366:69-72 (1991)	
	C26	WALTER et al., "Measurement of in Vivo DNA Binding by Sequence-Speciic Transcription Factors Using UV Cross-Linking," METHODS: a Companion to Methods in Enzymology 11:215-224 (1997)	
	C27	WEINMANN et al., "Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis," Genes & Development, 16:235-244, (2002)	
	C28	WYRICK et al., "Deciphering gene expression regulatory networks," Current Opinion in Genetics and Development, 12:130-136, (2002)	

Examiner Signature	/Kenneth Horlick/	Date Considered	05/27/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

1091347_1.DOC

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10032281
Filing Date	2001-12-21
First Named Inventor	John Wyrick et al.
Art Unit	1637
Examiner Name	Fredman, Jeffrey Norman
Attorney Docket Number	10050560-1

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							☐

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10032281
	Filing Date	2001-12-21
	First Named Inventor	John Wyrick et al.
	Art Unit	1637
	Examiner Name	Fredman, Jeffrey Norman
	Attorney Docket Number	10050560-1

/KH/	1	Francis Barany, Title: "The Ligase Chain Reaction In A PCR World", Department Of Microbiology, Hearst Microbiology Research Center, Cornell University Medical College, New York, NY 10021, pp. 1-12. (1991)	☐
	2		☐

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Kenneth Horlick/	Date Considered	05/27/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO.	APPLICATION NO.
3rd SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	0399.1212-005	10/032,281
	FIRST NAMED INVENTOR: John Wyrick	FILING DATE: December 21, 2001
June 27, 2005 (Use several sheets if necessary)	EXAMINER: Fredman, Jeffrey Norman	CONFIRMATION NO.: 4057 / GROUP: 1637

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AG			
	AH			
	AI			
	AJ			
	AK			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES	TRANSLATION NO
	AN					
	AM					
	AO					
	AP					
	AQ					

OTHER DOCUMENTS ***(Including Author, Title, Date, Pertinent Pages, Etc.)***

/KH/	AY2	Zhu, G., *et al.*, "Two Yeast Forkhead Genes Regulate the Cell Cycle and Pseudohyphal Growth," *Nature 406*:90-94 (July 2000).
/KH/	AZ2	Kumar, R., *et al.*, "Forkhead Transcription Factors, Fkh1p and Fkh2p, Collaborate with Mcm1p to Control Transcription Required for M-Phase," *Curr. Biol. 10*(15): 896-906 (2000).
	AR3	
	AS3	

EXAMINER	/Kenneth Horlick/	DATE CONSIDERED	05/27/2008